Clinical Trials Unit
Stanford University School of Medicine's Center for Advanced Dermatologic Investigation is the Dermatology Department's clinical trials unit.
The Center is home to 12-15 ongoing clinical studies, investigating the safety and efficacy of new and currently available drugs and over-the-counter medications. The Center works with Stanford's own panel on medical research, leading pharmaceutical companies,and the Food and Drug Administration to safely and ethically expand the medical field's knowledge of dermatologic treatments. New studies begin regularly, and the Center continues to recruit patients with skin aging, sun damage, skin cancer (including basal cell carcinomas), psoriasis, atopic dermatitis, rosacea, and other dermatologic diseases for ongoing studies.
Skin Aging Studies
We seek to understand the human aging processes as it relates to skin on a fundamental level. To this end, our studies focus on clinical and translational research efforts ranging from: (1) the analysis of gene changes which predispose individuals to exceptionally youthful skin to (2) molecular signatures that may be biomarkers for aging skin to (3) the careful study of new candidate agents which might affect the skin aging process.
Nonmelanoma Skin Cancer
Recent advances in our understanding of basal cell skin cancer biology have enabled the development of cutting edge study drugs which combat tumor growth. We are currently home to a number of clinical trials at the forefront of potential therapy for advanced or metastatic basal cell cancer. In addition, we seek to understand the biology of basal cell skin cancers and to identify molecular predictors for treatment success.
Acne Rosecea
This is a common and frustrating chronic inflammatory condition of the face, usually affecting older individuals. The causes of this complex condition are the subject of much study. Our clinical studies seek to identify new topical or oral medications to improve the symptoms of acne rosacea.
Contact
For more information, please email dermtrials@stanford.edu
Featured Clinical Trials
Type 1 Diabetes and the Brain in Children
The investigators have previously studied a group of young children with T1D using brain MRI, age-appropriate neurocognitive testing and continuous glucose monitoring, followed for 18 months. The investigators observed significant differences in gray matter volumes and white matter microstructure in the children with diabetes as compared to controls. These differences appeared to increase over time, with slower rates of brain growth in the T1D group (Mazelli, et al, Diabetes 2014; Barnea-Goraly, et al, Diabetes Care 2014; Mauras, et al, Diabetes 2015). In this new protocol the investigators will include the same children with T1D and healthy controls previously studied and recruit new similar subjects to replace those lost by attrition. The investigators will be using structural and functional brain MRI, neurocognitive testing and measures of glycemic control, to determine if changes in the brain persist or worsen over longitudinal follow up, and whether these changes are associated with measures of glycemic control and neurocognitive metrics as these children grow and progress through puberty.
Stanford is currently accepting patients for this trial.
Stanford Investigator(s):
Intervention(s):
- other: Observational
Eligibility
Inclusion Criteria for T1 Diabetes Group:
- Diabetes diagnosed after age 6 months
- Gestational age >34 weeks, birth weight >2kg
Inclusion Criteria for Healthy Control Group:
- Normal HbA1C and fasting blood glucose
- Negative diabetes auto-antibodies (those that are siblings of T1D patients)
- Gestational age >34 weeks, birth weight >2kg
Exclusion Criteria for Both Groups:
- History of mental retardation, language or learning disability
- Known genetic or medical problem that could impair brain development
- Abnormality of the brain/nervous system, visual or hearing problem
- History of seizures not associated with fever
- Previous inpatient psychiatric treatment
- Unable to have a MRI of the head due to metal appliances
Ages Eligible for Study
7 Years - 16 Years
Genders Eligible for Study
All
Now accepting new patients
Contact Information
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305
Recruiting
Psoriasis Clinical Trials
Type 1 Diabetes and the Brain in Children
The investigators have previously studied a group of young children with T1D using brain MRI, age-appropriate neurocognitive testing and continuous glucose monitoring, followed for 18 months. The investigators observed significant differences in gray matter volumes and white matter microstructure in the children with diabetes as compared to controls. These differences appeared to increase over time, with slower rates of brain growth in the T1D group (Mazelli, et al, Diabetes 2014; Barnea-Goraly, et al, Diabetes Care 2014; Mauras, et al, Diabetes 2015). In this new protocol the investigators will include the same children with T1D and healthy controls previously studied and recruit new similar subjects to replace those lost by attrition. The investigators will be using structural and functional brain MRI, neurocognitive testing and measures of glycemic control, to determine if changes in the brain persist or worsen over longitudinal follow up, and whether these changes are associated with measures of glycemic control and neurocognitive metrics as these children grow and progress through puberty.
Stanford is currently accepting patients for this trial.
Stanford Investigator(s):
Intervention(s):
- other: Observational
Eligibility
Inclusion Criteria for T1 Diabetes Group:
- Diabetes diagnosed after age 6 months
- Gestational age >34 weeks, birth weight >2kg
Inclusion Criteria for Healthy Control Group:
- Normal HbA1C and fasting blood glucose
- Negative diabetes auto-antibodies (those that are siblings of T1D patients)
- Gestational age >34 weeks, birth weight >2kg
Exclusion Criteria for Both Groups:
- History of mental retardation, language or learning disability
- Known genetic or medical problem that could impair brain development
- Abnormality of the brain/nervous system, visual or hearing problem
- History of seizures not associated with fever
- Previous inpatient psychiatric treatment
- Unable to have a MRI of the head due to metal appliances
Ages Eligible for Study
7 Years - 16 Years
Genders Eligible for Study
All
Now accepting new patients
Contact Information
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305
Recruiting
Dermatology Clinical Trials
Type 1 Diabetes and the Brain in Children
The investigators have previously studied a group of young children with T1D using brain MRI, age-appropriate neurocognitive testing and continuous glucose monitoring, followed for 18 months. The investigators observed significant differences in gray matter volumes and white matter microstructure in the children with diabetes as compared to controls. These differences appeared to increase over time, with slower rates of brain growth in the T1D group (Mazelli, et al, Diabetes 2014; Barnea-Goraly, et al, Diabetes Care 2014; Mauras, et al, Diabetes 2015). In this new protocol the investigators will include the same children with T1D and healthy controls previously studied and recruit new similar subjects to replace those lost by attrition. The investigators will be using structural and functional brain MRI, neurocognitive testing and measures of glycemic control, to determine if changes in the brain persist or worsen over longitudinal follow up, and whether these changes are associated with measures of glycemic control and neurocognitive metrics as these children grow and progress through puberty.
Stanford is currently accepting patients for this trial.
Stanford Investigator(s):
Intervention(s):
- other: Observational
Eligibility
Inclusion Criteria for T1 Diabetes Group:
- Diabetes diagnosed after age 6 months
- Gestational age >34 weeks, birth weight >2kg
Inclusion Criteria for Healthy Control Group:
- Normal HbA1C and fasting blood glucose
- Negative diabetes auto-antibodies (those that are siblings of T1D patients)
- Gestational age >34 weeks, birth weight >2kg
Exclusion Criteria for Both Groups:
- History of mental retardation, language or learning disability
- Known genetic or medical problem that could impair brain development
- Abnormality of the brain/nervous system, visual or hearing problem
- History of seizures not associated with fever
- Previous inpatient psychiatric treatment
- Unable to have a MRI of the head due to metal appliances
Ages Eligible for Study
7 Years - 16 Years
Genders Eligible for Study
All
Now accepting new patients
Contact Information
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305
Recruiting
Pediatric Dermatology Clinical Trials
Type 1 Diabetes and the Brain in Children
The investigators have previously studied a group of young children with T1D using brain MRI, age-appropriate neurocognitive testing and continuous glucose monitoring, followed for 18 months. The investigators observed significant differences in gray matter volumes and white matter microstructure in the children with diabetes as compared to controls. These differences appeared to increase over time, with slower rates of brain growth in the T1D group (Mazelli, et al, Diabetes 2014; Barnea-Goraly, et al, Diabetes Care 2014; Mauras, et al, Diabetes 2015). In this new protocol the investigators will include the same children with T1D and healthy controls previously studied and recruit new similar subjects to replace those lost by attrition. The investigators will be using structural and functional brain MRI, neurocognitive testing and measures of glycemic control, to determine if changes in the brain persist or worsen over longitudinal follow up, and whether these changes are associated with measures of glycemic control and neurocognitive metrics as these children grow and progress through puberty.
Stanford is currently accepting patients for this trial.
Stanford Investigator(s):
Intervention(s):
- other: Observational
Eligibility
Inclusion Criteria for T1 Diabetes Group:
- Diabetes diagnosed after age 6 months
- Gestational age >34 weeks, birth weight >2kg
Inclusion Criteria for Healthy Control Group:
- Normal HbA1C and fasting blood glucose
- Negative diabetes auto-antibodies (those that are siblings of T1D patients)
- Gestational age >34 weeks, birth weight >2kg
Exclusion Criteria for Both Groups:
- History of mental retardation, language or learning disability
- Known genetic or medical problem that could impair brain development
- Abnormality of the brain/nervous system, visual or hearing problem
- History of seizures not associated with fever
- Previous inpatient psychiatric treatment
- Unable to have a MRI of the head due to metal appliances
Ages Eligible for Study
7 Years - 16 Years
Genders Eligible for Study
All
Now accepting new patients
Contact Information
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305
Recruiting
Type 1 Diabetes and the Brain in Children
The investigators have previously studied a group of young children with T1D using brain MRI, age-appropriate neurocognitive testing and continuous glucose monitoring, followed for 18 months. The investigators observed significant differences in gray matter volumes and white matter microstructure in the children with diabetes as compared to controls. These differences appeared to increase over time, with slower rates of brain growth in the T1D group (Mazelli, et al, Diabetes 2014; Barnea-Goraly, et al, Diabetes Care 2014; Mauras, et al, Diabetes 2015). In this new protocol the investigators will include the same children with T1D and healthy controls previously studied and recruit new similar subjects to replace those lost by attrition. The investigators will be using structural and functional brain MRI, neurocognitive testing and measures of glycemic control, to determine if changes in the brain persist or worsen over longitudinal follow up, and whether these changes are associated with measures of glycemic control and neurocognitive metrics as these children grow and progress through puberty.
Stanford is currently accepting patients for this trial.
Stanford Investigator(s):
Intervention(s):
- other: Observational
Eligibility
Inclusion Criteria for T1 Diabetes Group:
- Diabetes diagnosed after age 6 months
- Gestational age >34 weeks, birth weight >2kg
Inclusion Criteria for Healthy Control Group:
- Normal HbA1C and fasting blood glucose
- Negative diabetes auto-antibodies (those that are siblings of T1D patients)
- Gestational age >34 weeks, birth weight >2kg
Exclusion Criteria for Both Groups:
- History of mental retardation, language or learning disability
- Known genetic or medical problem that could impair brain development
- Abnormality of the brain/nervous system, visual or hearing problem
- History of seizures not associated with fever
- Previous inpatient psychiatric treatment
- Unable to have a MRI of the head due to metal appliances
Ages Eligible for Study
7 Years - 16 Years
Genders Eligible for Study
All
Now accepting new patients
Contact Information
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305
Recruiting
Type 1 Diabetes and the Brain in Children
The investigators have previously studied a group of young children with T1D using brain MRI, age-appropriate neurocognitive testing and continuous glucose monitoring, followed for 18 months. The investigators observed significant differences in gray matter volumes and white matter microstructure in the children with diabetes as compared to controls. These differences appeared to increase over time, with slower rates of brain growth in the T1D group (Mazelli, et al, Diabetes 2014; Barnea-Goraly, et al, Diabetes Care 2014; Mauras, et al, Diabetes 2015). In this new protocol the investigators will include the same children with T1D and healthy controls previously studied and recruit new similar subjects to replace those lost by attrition. The investigators will be using structural and functional brain MRI, neurocognitive testing and measures of glycemic control, to determine if changes in the brain persist or worsen over longitudinal follow up, and whether these changes are associated with measures of glycemic control and neurocognitive metrics as these children grow and progress through puberty.
Stanford is currently accepting patients for this trial.
Stanford Investigator(s):
Intervention(s):
- other: Observational
Eligibility
Inclusion Criteria for T1 Diabetes Group:
- Diabetes diagnosed after age 6 months
- Gestational age >34 weeks, birth weight >2kg
Inclusion Criteria for Healthy Control Group:
- Normal HbA1C and fasting blood glucose
- Negative diabetes auto-antibodies (those that are siblings of T1D patients)
- Gestational age >34 weeks, birth weight >2kg
Exclusion Criteria for Both Groups:
- History of mental retardation, language or learning disability
- Known genetic or medical problem that could impair brain development
- Abnormality of the brain/nervous system, visual or hearing problem
- History of seizures not associated with fever
- Previous inpatient psychiatric treatment
- Unable to have a MRI of the head due to metal appliances
Ages Eligible for Study
7 Years - 16 Years
Genders Eligible for Study
All
Now accepting new patients
Contact Information
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305
Recruiting